Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX TM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results